ATE386507T1 - Mikropartikel - Google Patents

Mikropartikel

Info

Publication number
ATE386507T1
ATE386507T1 AT04075082T AT04075082T ATE386507T1 AT E386507 T1 ATE386507 T1 AT E386507T1 AT 04075082 T AT04075082 T AT 04075082T AT 04075082 T AT04075082 T AT 04075082T AT E386507 T1 ATE386507 T1 AT E386507T1
Authority
AT
Austria
Prior art keywords
microparticles
therapeutic agent
agent
spray
suspension
Prior art date
Application number
AT04075082T
Other languages
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE386507(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE386507T1 publication Critical patent/ATE386507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Disintegrating Or Milling (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Glanulating (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04075082T 1998-09-03 1999-09-03 Mikropartikel ATE386507T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles

Publications (1)

Publication Number Publication Date
ATE386507T1 true ATE386507T1 (de) 2008-03-15

Family

ID=10838317

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943130T ATE265204T1 (de) 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion
AT04075082T ATE386507T1 (de) 1998-09-03 1999-09-03 Mikropartikel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99943130T ATE265204T1 (de) 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion

Country Status (15)

Country Link
US (3) US20020197325A1 (de)
EP (2) EP1107737B1 (de)
JP (2) JP2002524411A (de)
CN (1) CN1315854A (de)
AT (2) ATE265204T1 (de)
AU (1) AU5640799A (de)
BR (1) BR9913456A (de)
CA (1) CA2342206C (de)
DE (2) DE69916856T2 (de)
DK (1) DK1107737T3 (de)
ES (2) ES2301929T3 (de)
GB (1) GB9819272D0 (de)
IL (1) IL141323A0 (de)
MX (1) MXPA01002323A (de)
WO (1) WO2000013668A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770235B2 (en) * 1999-03-08 2004-02-19 Powderject Research Limited Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
EP1399132A1 (de) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Herstellung von harten und dichten partikeln
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2603031A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Apparatus for treating particles and liquids by ultrasound
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
EP2647712A3 (de) 2006-08-04 2013-11-20 Baxter International Inc Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (de) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-mikro-Teilchen zur intradermalen Verabreichung
KR102034872B1 (ko) * 2018-01-10 2019-10-21 주식회사 지투지바이오 콜라겐 펩타이드가 함유된 폴리카프로락톤 미립구 필러 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
CA2146999A1 (en) * 1992-10-16 1994-04-28 Stephen John Douglas Taste-masking compositions of ranitidine
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
WO1995034291A1 (en) * 1994-06-15 1995-12-21 Dumex-Alpharma A/S Pellets
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
EP1410792B1 (de) 2008-02-20
EP1107737B1 (de) 2004-04-28
JP2006096755A (ja) 2006-04-13
CN1315854A (zh) 2001-10-03
EP1410792A8 (de) 2004-12-29
DE69916856T2 (de) 2005-04-21
MXPA01002323A (es) 2002-05-08
US20050002870A1 (en) 2005-01-06
DE69938201D1 (de) 2008-04-03
BR9913456A (pt) 2001-07-24
EP1410792A1 (de) 2004-04-21
US20020197325A1 (en) 2002-12-26
AU5640799A (en) 2000-03-27
ATE265204T1 (de) 2004-05-15
JP2002524411A (ja) 2002-08-06
CA2342206A1 (en) 2000-03-16
WO2000013668A1 (en) 2000-03-16
DE69938201T2 (de) 2009-02-12
EP1107737A1 (de) 2001-06-20
GB9819272D0 (en) 1998-10-28
US20070026081A1 (en) 2007-02-01
ES2223181T3 (es) 2005-02-16
CA2342206C (en) 2006-12-12
ES2301929T3 (es) 2008-07-01
DE69916856D1 (de) 2004-06-03
DK1107737T3 (da) 2004-08-02
IL141323A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
DE69938201D1 (de) Mikropartikel
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
HU913776D0 (en) Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents
NO961291L (no) Prosess II
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
GR3020355T3 (en) Aminosulfonyl urea acat inhibitors
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
ATE271852T1 (de) Verbesserte inhalationspräparate
BG105204A (en) Salts of paroxetine
JP2000319390A5 (de)
BG66081B1 (bg) Състави, съдържащи модафинилни съединения
NO995109L (no) Formuleringer inneholdende 1,2,4-benzotriazinoksyder
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
NO951762D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
ES8505968A1 (es) Procedimiento para preparar (6-(etil-(2-hidroxipropil)-amino)-3-piridazinil)-hidrazinocarboxilato de etilo
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
IT8803670A0 (it) Procedimento per la realizzazione di granuli, in particolare granuli sferoidali, ed apparecchiatura per l'attuazione di tale metodo
ZA200006695B (en) Granulator organosilane preparation, process for the production thereof and use thereof.
DE69829174D1 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)
NL1015302A1 (nl) Werkwijze voor de productie van 2,3-dimethylbuteen-1 en 2,3-dimethylbuteen-2.
ID28707A (id) 1,2,4-trioksan tersubstitusi sebagai obat anti malaria dan metode pembuatannya

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1410792

Country of ref document: EP

REN Ceased due to non-payment of the annual fee